EG 005 - Evergreen Therapeutics
Alternative Names: EG-005 - Evergreen TherapeuticsLatest Information Update: 05 Feb 2021
At a glance
- Originator Evergreen Therapeutics
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Asthma
Most Recent Events
- 22 Oct 2020 Shenzhen Evergreen Therapeutics has patents pending for formulations, methods and kits for treating auto-immune and auto-inflammatory diseases in USA
- 22 Oct 2020 Preclinical trials in Asthma in China (Inhalation) (Shenzhen Eglin Pharmaceutical pipeline, October 2020)
- 03 Mar 2019 Shenzhen Evergreen Therapeutics has patent protection for the use of progestogen as a glucocorticoid sensitizer methods in US, Japan, Europe and China